I help biotech CEOs make the commercial decisions that shape enterprise value, long before launch.
Here’s the bind I see again and again. A CEO is expected to have commercial answers they’ve never had to give, and to project confidence while the evidence isn’t in yet. The science got the company here. Now the questions are commercial: which indication, how big, when to build, what investors need to hear. And they get decided years before there’s a commercial team to own them. By then, the calls that mattered most are already made.
That’s the work at Kavros. I’m a fractional commercial partner and senior advisor for institutionally funded biotechs, on the highest-consequence decisions: lead asset selection, indication prioritization, how the asset is positioned to win, the investor and partner story, and when and how to build commercial capability.
